Tumor endothelial markers as a target in cancer
- 17 September 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Emerging Therapeutic Targets
- Vol. 16 (12), 1215-1225
- https://doi.org/10.1517/14728222.2012.725047
Abstract
Introduction: Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help to target endothelium and to identify potential predictive factors of response to anti-angiogenic therapies. Numerous surrogates, angiogenic and endothelium markers have emerged from recent pre-clinical studies, including physiological and soluble molecules in plasma and from platelets, circulating cells, tumor tissue factors and imaging markers. However, no wholly validated biomarkers currently exist to predict the success or the failure of the anti-angiogenic therapy of cancer. Therefore, the research of suitable and validate biomarkers is currently ongoing. Areas covered: This review provides an overview of the status of our knowledge concerning tumor endothelial markers, therapeutics targeting, possible resistance mechanisms and predictive value of these biomarkers and discuss future strategies to use and identify them in the anti-angiogenic therapy. Expert opinion: Anti-angiogenesis is a milestone to improve the treatment of several types of cancer and predictive biomarkers for a response to anti-endothelium therapy are one of the most important challenges for anti-angiogenesis research.Keywords
This publication has 101 references indexed in Scilit:
- Vascular endothelial-cadherin and vascular stabilityCurrent Opinion in Hematology, 2012
- Vascular disrupting agentsCurrent Opinion in Oncology, 2012
- Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolinVascular Cell, 2012
- Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptideProceedings of the National Academy of Sciences of the United States of America, 2011
- Targeted nanoagents for the detection of cancersMolecular Oncology, 2010
- Platelets actively sequester angiogenesis regulatorsBlood, 2009
- Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic CellsCancer Cell, 2008
- Platelet-associated PF-4 as a biomarker of early tumor growthBlood, 2008
- Display technologies: Application for the discovery of drug and gene delivery agentsAdvanced Drug Delivery Reviews, 2006
- Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth FactorCancer Research, 2006